CJC-1295 and ipamorelina are experimental peptides studied for their effects on the growth hormone (GH) system. Both substances can affect the secretion of GH, but they use different receptor pathways and differ in pharmacological properties.
CJC-1295 is associated with the action of growth hormone-releasing hormone (GHRH), whereas ipamorelina belongs to growth hormone secretagogues that act on the growth hormone receptor. This means that although both substances can affect the same hormonal axis, they do not act in the same way.
It is also important to distinguish between CJC-1295 with the DAC complex and a shorter-acting analog referred to in marketing materials as „CJC-1295 without DAC” or modified GRF (1–29). These names are sometimes used interchangeably, although they refer to forms with different chemical and pharmacokinetic properties.
On the internet, CJC-1295 and ipamorelina are often presented in the context of increasing muscle mass, reducing fat tissue, regeneration, sleep, and the aging process. However, such claims require a separation from the results of actual studies.
An increase in GH or insulin-like growth factor 1 (IGF-1) levels is not automatically evidence of improved body composition, physical fitness, metabolic health, or longevity.
The article presents the mechanisms of action of both peptides, the results of clinical and preclinical studies, differences between the forms of CJC-1295, and the most important limitations of the available scientific evidence.
What are CJC-1295 and ipamorelina?
CJC-1295 and ipamorelina are substances that have been studied in the context of regulation of the secretion of growth hormone.
Both affect mechanisms related to the activity of somatotropic cells in the brain, but their main receptor targets are different.
CJC-1295 as a modified GHRH analog
Growth hormone-releasing hormone, or GHRH, is a natural signal produced in the hypothalamus.
It acts on receptors present on somatotropic cells of the anterior pituitary lobe. The stimulation of these receptors is involved in the regulation of GH secretion, which subsequently affects, among other things, the concentration of circulating IGF-1.
CJC-1295 was developed as a modified analog of GHRH.
In the original long-acting form, a modification was used that allows it to bind to albumin, one of the main proteins in the blood plasma.
This solution was intended to extend the exposure time of the body to the active substance [3,7].
In the materials describing CJC-1295, one can find a summary formula C₁₅₂H₂₅₂N₄₄O₄₂, a molecular mass of about 3367.9 g/mol, and information about the modified sequence associated with the 29-amino acid fragment of GHRH.
However, such parameters should always be related to an exactly defined chemical form.
The presence or absence of DAC modifications, the type of chain ends, and other structural elements can affect the identity and mass of the molecule.
The mere trade name CJC-1295 is therefore not sufficient to unequivocally confirm the structure of a particular substance.
CJC-1295 with and without DAC – why is this distinction important?
CJC-1295 with DAC contains a chemical modification that allows for prolonged binding to circulating blood albumin.
This affects the duration of the substance’s presence in the body and the course of the hormonal response.
In turn, the term „CJC-1295 without DAC” is often used in reference to modified GRF (1–29), which is a related, shorter-acting analog of GHRH.
Despite the similarity of the fragment responsible for interaction with the receptor, these compounds should not be considered pharmacologically identical.
They can differ in terms of exposure time, the course of the response to a specific concentration, and the characteristics of the hormonal action.
Distinction is particularly important when interpreting clinical studies.
The most well-known studies of CJC-1295 in humans concerned the long-acting form containing DAC.
Therefore, it is not possible to automatically transfer their results to modified GRF (1–29) without DAC.
It should also not be assumed that DAC only changes the half-life, without affecting other aspects of the biological response.
The exposure time may be important for the way in which the hormonal axis is stimulated and the consequences of such stimulation.
How does ipamorelina work?
Imipramine, described in early studies as NNC 26-0161, belongs to the secretagogues of growth hormone.
Its main target is the ghrelin receptor, known as GHSR1a.
This is a different receptor system than that to which GHRH analogs act.
Early pharmacological studies analyzed the GH response after exposure to ipamorelin and tested whether its hormonal profile is more selective than that of some other growth hormone secretagogues [8,14].
The selectivity observed in a particular experiment does not, however, mean that the substance does not cause other physiological effects.
It also does not confirm the safety of prolonged exposure.
Because CJC-1295 and ipamorelina act on different receptors, scientists can study possible interactions between these pathways.
However, the mechanistic explanation alone is not evidence that the combination of both substances provides clinical benefits.
What do the studies of CJC-1295 with DAC in humans show?
The most important clinical studies of CJC-1295 focused on pharmacokinetics, GH secretion, IGF-1 concentrations, and short-term tolerance.
These were not studies designed primarily to assess muscle mass growth, regeneration, reduction of fat tissue, or anti-aging effects.
Long-term changes in GH and IGF-1 in healthy adults
Teichman and colleagues (2006) evaluated the pharmacokinetics, growth hormone response, IGF-1 concentration and tolerance of the long-acting CJC-1295 in healthy adult subjects.
The study observed clear and sustained changes in the levels of GH and IGF-1.
The authors described a two- to ten-fold increase in the measured GH levels that persisted for at least six days.
The IGF-1 concentration increased approximately 1.5–3 times, and the observed effect persisted for approximately 9–11 days after a single administration, depending on the parameter analyzed and the experimental conditions [3].
These results indicate pharmacodynamic activity of the long-acting form of CJC-1295.
However, they do not demonstrate an increase in muscle mass, an improvement in sports performance, an acceleration of tissue healing, a reduction in fat tissue, or a slowing of aging.
The study primarily aimed to determine the hormonal response and short-term tolerance.
The absence of serious adverse events in the limited trial does not rule out rare adverse effects or consequences of repeated, prolonged exposure.
Pulsatile secretion of GH and primary secretion
Ionescu and Frohman (2006) analyzed the pattern of GH secretion after the administration of a long-acting analog of GHRH.
The study found that the pulsatile secretion of growth hormone remained detectable during prolonged stimulation.
At the same time, the basic secretion of GH increased.
An approximately 46 percent increase in total GH secretion was described, as well as an approximately 45 percent increase in IGF-1 concentration, and significant changes in the basic parameters of hormone secretion [4].
These results require precise interpretation.
Maintaining GH levels does not mean that the entire hormonal system functions identically without exposure to the substance.
It also does not confirm the absence of metabolic risk.
The increase in baseline GH secretion, changes in pulse rate, and the increase in IGF-1 are separate observations.
It should not be reduced to a simplistic statement that CJC-1295 merely „supports the natural hormonal rhythm”.
There is also no basis for directly converting the observed changes in GH to equivalent amounts of externally administered growth hormone.
Endogenous secretion, hormone concentration in the blood, and the dose of exogenous GH are not mutually interchangeable quantities.
Changes in plasma proteins as experimental biomarkers
Sackmann-Sala and colleagues (2009) studied changes in the serum protein profile after activation of the GH/IGF-1 axis by CJC-1295.
In a small study in humans, differences were identified in several protein signals and their relationship with IGF-1 changes were analyzed.
They included, among other things, signals attributed to apolipoprotein A1, transthyretin, hemoglobin-related material, albumin fragments, and components associated with immunoglobulins [5].
Such observations may be relevant for research on biomarkers.
However, this does not mean that the detected proteins constitute validated indicators of the efficacy or safety of CJC-1295.
The association between a change in the protein profile and the hormonal response is not automatically evidence of predicting a specific clinical effect.
Such an application would require independent studies to confirm the results, appropriate analytical methods, and evaluation in larger populations.
What do preclinical studies of CJC-1295 contribute?
Preclinical studies allow the analysis of the mechanisms of action of substances in controlled biological models.
However, their results depend on the species, the characteristics of the model, and the conditions of the experiment.
Model of mice with severe GHRH deficiency
Alba and colleagues (2006) studied the long-acting analog of GHRH in mice genetically deprived of this hormone.
This model causes a clear disruption of the proper functioning of the growth hormone axis.
Changes in growth, body composition, and parameters related to the pituitary gland were observed in the experiment.
The nature of the results depended on the experimental scheme used [6].
The study was important for evaluating the activity of a GHRH analog under conditions of profound hormonal deficiency.
However, this does not mean that similar effects will occur in healthy adults with normal GH secretion.
It also does not confirm its use in the context of aging, sports goals, or improving body composition in humans.
The severe deficiency of GHRH in the genetic model differs significantly from the physiology of individuals without such a disorder.
Binding with albumin and prolonged exposure
Jetté and colleagues (2005) analyzed analogs of GHRH capable of binding to albumin.
In preclinical studies, CJC-1295 was identified as a long-acting analog whose properties were associated with prolonged exposure while maintaining the ability to activate the appropriate pituitary receptor [7].
The study helps to explain the mechanism of action of DAC modification.
It also shows why the long-acting form of CJC-1295 should not be confused with the shorter-acting analog without DAC.
However, this was not a direct study of the combination of CJC-1295 and ipamorelin.
The results cannot therefore be considered as confirmation of the clinical superiority of such a combination.
What have the studies of ipamorelin in humans shown?
Studies of ipamorelin in humans included, among other things, analysis of pharmacokinetics, growth hormone responses and evaluation of specific clinical outcomes following intestinal surgeries.
However, these data do not confirm all the uses attributed to the substance in commercial materials.
Pharmacokinetics and the growth hormone response
Gobburu and colleagues (1999) used pharmacokinetic-pharmacodynamic modeling to analyze ipamorelin in volunteers.
The researchers analyzed the relationship between the concentration of the substance in the plasma and the GH response.
The relatively short terminal half-life of ipamorelin has been described compared to the long-acting form of CJC-1295 containing DAC.
In the analyzed material, the GH response reached a maximum approximately 40 minutes after administration.
The researchers also presented model estimates of the strength of the action and the rate of production of growth hormone [14].
The results allow characterizing the pharmacological activity of ipamorelin in the studied population.
However, they do not specify an optimal treatment regimen or long-term safety.
They also do not confirm improvements in body composition, sleep quality, cognitive performance, or physical fitness.
An additional limitation is individual variability.
The population model does not guarantee an identical response in every person.
Randomized study of postoperative stricture of the mesenteric vessels
Beck and colleagues (2014) evaluated ipamorelin in a randomized, placebo-controlled study involving patients after intestinal resection.
The study was of a proof-of-concept nature, that is, an initial assessment of a specific therapeutic concept.
The main area of interest concerned the return of the gastrointestinal tract functions after the operation.
It did not analyze the improvement in athletic performance or the overall optimization of growth hormone.
The median time to tolerate a steady meal was 25.3 hours in the ipamorelin group and 32.6 hours in the placebo group.
However, this difference did not reach statistical significance. The p-value given was 0.15 [11].
This means that the numerical difference alone is not sufficient to confirm clinical effectiveness.
Information about adverse effects should also be interpreted with caution.
The high frequency of medical events in patients after surgeries makes it impossible to determine without further analysis which of them were related to the substance under investigation.
The study provides clinical data in a specific surgical context.
However, it does not confirm the wide applications of ipamorelin in the wellness field.
What did the studies on ipamorelin in animals show?
Preclinical literature regarding ipamorelin covers various biological systems.
Among other things, growth of bone, the content of bone minerals, the functioning of the digestive tract, pituitary cells, the reproductive system, metabolism, and the response to experimentally induced diseases were studied.
The results of these experiences require separation from clinical evidence.
Bone growth, mineralization and musculoskeletal parameters
Johansen and colleagues (1999) analyzed the effect of ipamorelin on the longitudinal growth of bones and body weight in rats.
Under certain experimental conditions, changes in growth-related parameters were observed [8].
The results were consistent with the researchers’ interest in the biological effects of GH secretagogues.
However, this does not mean that ipamorelina increases bone strength or reduces the risk of fractures in adult people.
Svensson and colleagues (2000) studied the mineral content of bone and structural parameters in adult female rats.
In some of the measurements, an increase in mineral content was observed, which was partly related to changes in bone size [13].
It is necessary to distinguish between the content of bone minerals, mineral density, bone geometry, and their resistance to fractures.
Improving one parameter does not automatically mean improving all the others.
Andersen and colleagues (2001) evaluated the effect of ipamorelin on bone changes associated with glucocorticosteroid exposure in rats.
In this model, changes were observed regarding bone formation and selected parameters of the musculoskeletal system [12].
However, this does not confirm the effectiveness of ipamorelin in the treatment of postmenopausal osteoporosis or muscle weakness in humans.
Motoric disorders of the alimentary tract and postoperative intestinal obstruction
Venkova and colleagues (2009) studied ipamorelin in a model of postoperative obstruction of the mesenteric vessels in rodents.
The intestinal tract was analyzed, fecal excretion, food intake, and other indicators of the return of intestinal function were assessed.
Some of these parameters improved under experimental conditions [9].
Greenwood-Van Meerveld and colleagues (2012) also evaluated gastric dysfunction after experimental intestinal manipulation in rodents.
Changes in gastric emptying and contractile responses have been described [10].
These studies helped to justify further clinical evaluation of ipamorelin.
However, they do not replace the results of human studies.
In a later randomized clinical trial, the difference in the tolerance of a regular meal did not reach statistical significance [11].
Studies of somatotropic pituitary cells
Jiménez-Reina and colleagues (2002) analyzed pituitary somatotropic cells in young female rats after repeated exposure to ipamorelin.
The study included the evaluation of the ultrastructure of the cells and their responses to subsequent stimulation in vitro conditions [15].
The observed changes concerned specific morphological characteristics and experimental responses.
However, on this basis, it cannot be concluded that prolonged exposure to ipamorelin is safe for humans.
The number of secretory granules, the intracellular content of GH, and the ratios of different cell types are mechanistic indicators.
They do not constitute direct evidence of an improvement in hormonal health.
The reproductive system in fish studies
Gouda and Ganesh (2024) studied ipamorelin acetate in Mozambique tilapia.
The experiment evaluated the development of reproductive cells and hormone markers, including luteinizing hormone, 11-ketotestosterone, and parameters related to the androgen receptor [16].
Changes were observed in selected indicators of the reproductive system.
These results are interesting from the perspective of comparative endocrinology.
However, they cannot be directly related to fertility, testosterone levels, or sperm production in men.
The physiology of fish reproduction is significantly different from that of humans.
Changes in appetite and body weight in the cisplatin action model
Lu and colleagues (2024) analyzed the agonists of the glucocorticoid receptor in a model of cisplatin-induced disease in ferrets.
Changes in body weight, food and water intake, parameters related to vomiting, and the response of the gastrointestinal tract tissues were examined among others.
Some results suggested the effect of ipamorelin on weight loss and nutritional-related parameters in this model [17].
However, such observations do not confirm the effectiveness in patients undergoing chemotherapy.
It is also not possible to attribute all the effects observed for other studied G-receptor agonists, such as anamnoreline, to ipamorelin.
Insulin secretion in isolated pancreatic tissue
Adeghate and Ponery (2004) studied the secretion of insulin from pancreatic tissue obtained from healthy rats and rats with diabetes.
The response to ipamorelin and the involvement of calcium-dependent mechanisms and adrenergic signaling were analyzed [18].
The results suggested the possibility that ipamorelin could affect endocrine processes beyond the mere secretion of GH.
However, they do not allow for predicting the complete effect of the substance on the blood glucose concentration in humans.
They do not confirm the effectiveness in the treatment of diabetes or the absence of the risk of insulin resistance.
Studies of isolated tissues provide information about specific mechanisms, but do not reproduce the full metabolic regulation of the organism.
What is known about the pharmacokinetics of imaporemylin?
Pharmacokinetics describes the processes related to the absorption, distribution, metabolism, and elimination of substances.
Johansen and colleagues (1998) compared the pharmacokinetic properties of ipamorelin and other peptide-secreted growth hormone (GH) peptides in various experimental systems.
Among other things, elimination and absorption after administration were analyzed.
Differences regarding the clearance and excretion of individual substances have been described [19].
Results obtained in one species or for a specific formulation cannot be directly transferred to other conditions.
Bioavailability depends, among other things, on the route of administration, the product form, chemical properties, and the organism being studied.
Similarly, the detection of unchanged substance in the excreted material does not mean that the entire amount administered remained pharmacologically active throughout the entire period.
Individual information was provided by pharmacokinetic-pharmacodynamic modeling conducted by Gobburu and colleagues in humans [14].
Overall, these studies indicate that ipamorelina exhibits measurable pharmacological activity.
However, they do not establish a validated method for self-administration or a safe long-term exposure schedule.
Are there any evidence of the effectiveness of the combination of CJC-1295 and ipamorelin?
CJC-1295 and ipamorelina act on different mechanisms regulating GH secretion.
For this reason, the combination of both substances represents a possible topic for research into hormonal interactions.
However, this is not equivalent to confirmation of clinical benefits.
Why do researchers consider combining these peptides?
CJC-1295 and related GHRH analogs act on the GHRH receptor.
Imipramine, on the other hand, activates the ghrelin receptor GHSR1a.
Both pathways can influence the activity of somatotropic pituitary cells.
It is therefore possible to hypothesize that their simultaneous stimulation leads to a specific hormonal interaction.
However, it is not known whether such interaction translates into clinically relevant effects.
Available studies of individual substances do not confirm that their combination increases muscle mass, reduces fat tissue, improves sleep, cognitive function, immunity, skin appearance, or regeneration in humans.
Claims regarding synergy require direct, controlled research.
Promotional materials and internet descriptions of combinations may present hypotheses, but they do not have the same evidentiary value as clinical studies.
How should the study of such a connection look like?
A reliable study of combinations should make it possible to distinguish the effects of each substance from the effects of their simultaneous use.
The chemical form of CJC-1295 should be clearly defined and appropriate comparison groups should be included.
It would be important to have previously defined endpoints, an appropriate number of participants and sufficient observation time.
In addition to changes in GH and IGF-1, clinical results and adverse events should be evaluated.
The parameters of the glucose economy and the consequences of prolonged stimulation of the GH/IGF-1 axis would also be important.
The results of CJC-1295 studies with DAC cannot be automatically attributed to a form without DAC.
Similarly, the studies of ipamorelin itself do not prove the effectiveness of the combined preparation.
The lack of direct comparative studies means a gap in the evidence, not confirmation of equivalence.
CJC-1295 and ipamorelina and the administration of growth hormone
Externally administered growth hormone provides the body with a ready-made hormone.
Analogues of GHRH and GH secretagogues, on the other hand, act on the mechanisms regulating its endogenous secretion.
This is an important mechanistic difference.
However, this does not mean that stimulating the secretion of your own GH is automatically safer, more physiological, or more effective than administering the hormone externally.
The answer depends on the type of substance, formulation, exposure time, individual physiology, and the parameter being evaluated.
There is no basis for simply opposing exogenous GH as a substance that only causes adverse concentration spikes, and CJC-1295 and ipamorelin as compounds that maintain an ideal hormonal rhythm.
Such a comparison would require appropriately designed direct studies.
Without them, claims about the superiority of effectiveness, safety, or health benefits remain hypotheses.
Comparison of CJC-1295 with DAC, modified GRF (1–29), and ipamorelin
| Research question | CJC-1295 with DAC | Modified GRF (1–29), referred to as „No DAC” | Ipamorelin |
|---|---|---|---|
| The main receptor pathway | GHRH receptor | GHRH receptor | GHSR1a receptor |
| Characteristic property | Binding with albumin and prolonged exposure | A shorter-acting analog with a different exposure profile | Another receptor and pharmacological profile |
| Research in humans discussed in the article | Studies of GH and IGF-1 responses | Limited direct data in the cited literature | Modeling of the GH response and investigation of postoperative intestinal obstruction |
| Confirmed increase in muscle mass in humans | No evidence was found in the studies cited | Not demonstrated | Not demonstrated |
| Confirmed anti-aging effect | Not | Not | Not |
| Evidence of the effectiveness of the CJC-1295 and ipamorelin combination | They do not result from the study of a single substance | Not established | They do not result from the study of a single substance |
What are the uncertainties regarding safety and regulatory status?
The studies of CJC-1295 and ipamorelin differ in terms of number of participants, observation duration, biological model, and evaluated parameters.
Some publications present data on short-term tolerance or specific adverse events.
However, this is not equivalent to a full assessment of safety.
The GH/IGF-1 system is involved in the regulation of metabolic and growth processes.
Therefore, hormonal changes should be analyzed with caution, without assuming that greater GH secretion always means a beneficial effect.
In discussions regarding these substances, reactions at the injection site, headaches, nausea, and other vague symptoms are mentioned, among other things.
Based on the available mixture of early studies, preclinical experiments, and online reports, it is not possible to reliably determine the frequency of all such events or their causal relationship with a specific product.
The risk assessment also depends on the identity of the substance, its quality, the composition of the formulation, and the characteristics of the population being studied.
Validated regimens for the self-administration of the CJC-1295 and ipamorelin combinations have not been established.
The studies cited also do not confirm predictable results after a certain number of weeks or months.
They also do not provide sufficient grounds for recommending these substances to specific age groups.
The availability of products for sale is not proof of their approval for marketing as medicinal products or of their pharmaceutical quality.
How to properly interpret the studies of CJC-1295 and ipamorelin?
The strongest direct data in the cited literature concern the hormonal response to CJC-1295 with DAC, as well as the pharmacokinetics and pharmacodynamics of ipamorelin.
There are also clinical studies of ipamorelin in a specific post-operative context.
The remaining publications mainly describe animal models and experiments on tissues.
They analyze, among other things, bone growth, the function of the digestive tract, reproductive processes, the secretion of insulin, and the functioning of the pituitary cells.
These results should not be combined into a single general statement about therapeutic efficacy.
An increase in hormone levels is a change in a biomarker.
The result obtained in animals is pre-clinical evidence.
The numerical difference, which did not reach statistical significance in the clinical study, remains uncertain.
These distinctions are fundamental for a reliable assessment of both substances.
Frequently asked questions about CJC-1295 and ipamorelin
1. Is CJC-1295 the same as modified GRF (1–29)?
Not exactly. The name CJC-1295 is used inconsistently, especially in commercial offerings. The long-acting CJC-1295 studied in major clinical trials contains a DAC-related modification, whereas modified GRF (1–29), often referred to as „CJC-1295 without DAC”, has a different chemical and pharmacokinetic profile. Results regarding one form cannot be automatically used as evidence of efficacy or safety for the other.
2. What changes does the presence of DAC in CJC-1295 bring?
The DAC modification allows for extended binding of CJC-1295 to albumin, affecting the time the body is exposed to the substance. This is important for the course of the GH and IGF-1 responses. DAC should not be described as a component that only changes the half-life without any other pharmacological consequences. Changing the exposure time can also affect the nature of the hormonal stimulation [7].
3. Do human studies confirm that CJC-1295 increases GH and IGF-1?
Yes, but this primarily applies to the long-acting form of CJC-1295 with DAC, which was evaluated in the aforementioned studies. In healthy adults, sustained increases in GH and IGF-1 levels were observed. These are pharmacodynamic results, not direct evidence of muscle mass growth, improved physical performance, reduction in fat tissue, or slowing of aging [3].
4. Does CJC-1295 maintain natural pulsatile secretion of GH?
In one study in humans, it was found that pulsatile GH secretion remained detectable during prolonged stimulation with CJC-1295 with DAC. At the same time, the basal secretion of the hormone increased. This does not mean that the entire hormonal pattern was identical to the physiological state without exposure to the substance. The pulsatile behavior is also not evidence of long-term safety [4].
5. Does ipamorelina act on the same receptor as CJC-1295?
No. Ipamorelin acts primarily through the ghrelin receptor GHSR1a, whereas CJC-1295 and related GHRH analogs act on the GHRH receptor. Both pathways are involved in the regulation of growth hormone secretion, but they are mechanistically different. This does not automatically mean that simultaneous stimulation of both receptors provides a clinically significant synergy.
6. Does the combination of CJC-1295 and ipamorelin increase muscle mass in humans?
The literature cited does not include a controlled clinical study confirming that the combination of CJC-1295 and ipamorelin increases muscle mass or strength in humans. Changes in GH and IGF-1 are not sufficient evidence of such an effect. Also, skeletal muscle studies in rodents do not substitute for the direct assessment of body composition and muscle function in clinical trials.
7. Are there any evidence that this combination reduces the amount of fat tissue?
This has not been demonstrated in controlled studies of the combinations presented in the cited literature. Although growth hormone participates in the regulation of metabolism, the physiological compound itself does not confirm that a specific combination of experimental peptides causes a clinically significant reduction in body fat. Direct studies with appropriate comparison groups and measurements of body composition would be necessary.
8. What did the study of ipamorelin show in patients after intestinal surgery?
A randomized study by Beck and colleagues analyzed the return of gastrointestinal function after intestinal resection. The median time to tolerance of a solid meal was shorter in the ipamorelin group than in the placebo group, but the difference did not reach statistical significance. Therefore, the result does not confirm efficacy for this endpoint or for other clinical applications [11].
9. Do studies on the bones of rats confirm the effect of ipamorelin in osteoporosis?
No. Studies in rats have shown changes in bone growth, formation, and mineral content under certain experimental conditions. However, they do not confirm a reduction in the risk of fractures or effective treatment of osteoporosis in humans. Mineral content, bone density, geometry, and mechanical strength are separate parameters that should not be confused [12,13].
10. Does ipamorelina improve digestion in humans?
There is insufficient evidence to support such a general claim. Changes in stomach emptying and intestinal function have been observed in animal models, which justified further clinical studies. However, in the sample of patients after intestinal resection, the difference in tolerance to a regular meal was not statistically significant. Preclinical results therefore do not allow the conclusion that ipamorelina improves digestion in the general population [9,11].
11. Does ipamorelina increase testosterone or improve fertility?
This has not been confirmed in the studies cited in humans. A study on reproductive parameters was conducted in Mozambique tilapia, analyzing, among other things, the development of reproductive cells and specific hormonal markers. Fish reproductive physiology differs from human physiology. Therefore, such results cannot be used as evidence of increased testosterone levels, improved sperm production, or fertility in men [16].
12. Can ipamorelina affect insulin secretion?
The study of isolated pancreatic tissue from rats revealed responses related to insulin secretion and specific signaling mechanisms. This is mechanistic evidence, but not confirmation of improved glycemic control in humans. The result also does not mean that ipamorelina is metabolically inert or that prolonged stimulation of the GH axis is not associated with the risk of glucose metabolism disorders [18].
13. Are CJC-1295 and ipamorelina safe with prolonged exposure?
The available data do not allow for formulating a comprehensive long-term safety recommendation. Small studies and short observation periods may provide information about specific reactions and adverse events, but they are insufficient to detect all rare or delayed effects. The safety assessment must take into account the specific substance, formulation, population, and exposure time.
14. Do the CJC-1295 studies with DAC allow determining the dosage of forms without DAC?
No. CJC-1295 with DAC and modified GRF (1–29) without DAC have different exposure profiles, therefore the results of studies with one form cannot automatically determine the regimen for the other. The cited literature also does not confirm the online schedules for self-administration or the cycles of combining the two peptides. The article does not provide instructions for dosage, reconstitution, or injection.
15. What is the most important question regarding the combination of CJC-1295 and ipamorelin?
The most important unknown remains whether the precisely defined combination of both substances provides clinically relevant effects greater than either of them alone, with an acceptable safety profile. An answer requires controlled human studies, appropriate comparison groups, previously defined endpoints, and sufficient long-term follow-up. Receptor justification cannot replace such data.
Applications
CJC-1295 with DAC and ipamorelina show documented activity in the system that regulates the secretion of growth hormone.
However, this does not mean that their clinical efficacy has been confirmed in a wide range of applications.
Studies of CJC-1295 with DAC in humans have shown changes in GH and IGF-1, but do not constitute evidence of improvements in body composition, athletic performance, regeneration, or lifespan.
Imipramine was studied in humans regarding hormonal response and postoperative gastrointestinal function. In the cited clinical trial, the key outcome regarding the tolerance of a constant meal did not reach statistical significance.
Preclinical studies provided additional information about the skeletal system, gut function, reproductive processes, insulin secretion, and adrenal cell activity.
However, these observations cannot be directly translated into therapeutic efficacy in humans.
Special caution is required when distinguishing CJC-1295 from DAC and modified GRF (1–29) without DAC.
The different pharmacokinetic profile means that the results of the study of one form should not be automatically attributed to the other.
The evidence gap regarding the combination of CJC-1295 and ipamorelin remains equally important.
The hypothesis of a possible interaction between two receptor pathways is a valid subject of research, but it does not confirm the clinical efficacy or safety of the combination.
Disclaimer
The article is purely educational and scientifically informational in nature. It does not constitute medical advice, diagnosis, therapeutic recommendations, or instructions for the administration, reconstitution, or administration of experimental peptides.
CJC-1295 and ipamorelina are investigational substances, and the results presented do not establish their efficacy or safety in the applications discussed in the commercial materials.
Laboratory and animal studies should not be equated with confirmed clinical effects in humans. Evaluation of interventions affecting the hormonal system requires appropriate clinical knowledge and analysis of data regarding the specific substance and population.
References
- Van Hout, Marie Claire; Hearne, Evelyn . (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance Use & Misuse, (), 1–12. doi:10.3109/10826084.2015.1082595 https://pismin.com/10.3109/10826084.2015.1082595
- https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf
- Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P. and Frohman, L.A., 2006. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), pp.799-805. https://academic.oup.com/jcem/article-abstract/91/3/799/2843281
- Ionescu, M. and Frohman, L.A., 2006. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), pp.4792-4797. https://academic.oup.com/jcem/article-abstract/91/12/4792/2656274?login=false
- Sackmann-Sala, L., Ding, J., Frohman, L.A. and Kopchick, J.J., 2009. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in changes in serum protein profile in normal adult subjects. Growth Hormone & IGF Research, 19(6), pp.471-477. https://www.sciencedirect.com/science/article/abs/pii/S1096637409000409
- Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Frohman, L.A. and Salvatori, R., 2006. Daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), pp.E1290-E1294. https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF) 1-29 albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286 https://pubmed.ncbi.nlm.nih.gov/15817669/
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. doi:10.1054/ghir.1999.9998 https://pubmed.ncbi.nlm.nih.gov/10373343/
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. doi:10.1124/jpet.108.149211 https://pubmed.ncbi.nlm.nih.gov/19289567/
- Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E. and Pietra, C., 2012. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, pp.149-155. https://www.tandfonline.com/doi/abs/10.2147/JEP.S35396
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8 https://pubmed.ncbi.nlm.nih.gov/25331030/
- Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. doi:10.1054/ghir.2001.0239 https://pubmed.ncbi.nlm.nih.gov/11735244/
- Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. doi:10.1677/joe.0.1650569 https://pubmed.ncbi.nlm.nih.gov/10828840/
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402 https://pubmed.ncbi.nlm.nih.gov/10496658/
- Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-714. doi:10.14670/HH-17.707 https://pubmed.ncbi.nlm.nih.gov/12168778/
- Gouda M, Ganesh CB. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024;268:107550. doi:10.1016/j.anireprosci.2024.107550 https://pubmed.ncbi.nlm.nih.gov/38996787/
- Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. doi:10.1016/j.physbeh.2024.114644 https://pubmed.ncbi.nlm.nih.gov/39043357/
- Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004;25(6):403-406. https://pubmed.ncbi.nlm.nih.gov/15665799/
- Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-1092. doi:10.1080/004982598238976 https://pubmed.ncbi.nlm.nih.gov/9879640/
- https://www.dcreport.org/2024/11/21/potential-implications-of-cjc-1295-and-ghrp-6-blend-in-cellular-and-molecular-research/
- https://www.theclintoncourier.net/2024/09/05/cjc-1295-and-ipamorelin-blend-a-speculative-approach-to-peptide-research/
- https://antiagingnorthwest.com/understanding-different-ipamorelin-cjc-1295-dosages/